Clearside Biomedical, INC

Clearside Biomedical, Inc. secured court approval for its asset sale bidding procedures and designated Health Ocean Limited as the stalking horse bidder, while also filing its initial monthly operating report.

Clearside Biomedical, Inc. has completed its delisting from The Nasdaq Stock Market LLC and transferred trading to the OTC Pink Limited Market following its Chapter 11 bankruptcy filing.

Clearside Biomedical has filed for Chapter 11 bankruptcy and faces delisting from Nasdaq, aiming to sell its assets.

Clearside Biomedical, Inc. announced it has regained compliance with Nasdaq's Minimum Bid Price Requirement, resolving a prior delisting threat.

Clearside Biomedical, Inc. has filed an amendment to its certificate of incorporation to effect a 1-for-15 reverse stock split and reduce its authorized common shares.

Clearside Biomedical, Inc. will implement a 1-for-15 reverse stock split and reduce authorized common shares, effective September 12, 2025.

Clearside Biomedical reports significant financial challenges, including a going concern warning and a strategic review, despite reduced net losses.

Clearside Biomedical reports significant losses, a going concern warning, and a workforce reduction while actively exploring strategic alternatives and facing Nasdaq delisting.

Clearside Biomedical announces its Q1 2025 financial results, highlighting a net loss of $8.2 million and progress in its CLS-AX clinical program for wet AMD.

Clearside Biomedical announced positive topline results from its Phase 2b ODYSSEY trial for CLS-AX in wet AMD and provided a financial update for the third quarter of 2024, highlighting ongoing research and development efforts and financial challenges.

Clearside Biomedical reported a net loss of $19.4 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.

Clearside Biomedical's first quarter 2024 results show increased operating expenses due to ongoing clinical trials, alongside a net loss, but also highlight a recent capital raise and progress in their clinical programs.

Clearside Biomedical's 2024 10-K filing reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite positive clinical trial results and strategic partnerships.

Clearside Biomedical's 10-K filing highlights its focus on suprachoroidal drug delivery, pipeline development, and strategic collaborations, while also detailing financial results and risks.

Director Thorp Clay of Clearside Biomedical, Inc. (CLSD) acquired 15,000 shares of common stock at an average price of $0.92 on February 24, 2025, increasing their total holdings.

Charles A. Deignan, CFO of Clearside Biomedical, Inc., acquired 200,000 employee stock options on January 8, 2025.

Clearside Biomedical's Chief Medical Officer, Ngai Hang Victor Chong, was granted employee stock options to purchase 250,000 shares of common stock on January 8, 2025.

Clearside Biomedical CEO George M. Lasezkay acquired 500,000 employee stock options on January 8, 2025, exercisable at $0.97 per share.

Ngai Hang Victor Chong, Chief Medical Officer of Clearside Biomedical, reports acquiring 36,500 shares of common stock at $1 and disposing of 100,000 shares on November 1, 2024.

Ngai Hang Victor Chong, Chief Medical Officer of Clearside Biomedical, recently purchased 23,500 shares of common stock at a price of $1.06 per share.

Clearside Biomedical, Inc. will hold a Special Meeting to approve a reverse stock split to regain Nasdaq listing compliance.

Clearside Biomedical is holding its annual stockholder meeting on May 30, 2025, to vote on key proposals including the election of directors, executive compensation, auditor ratification, and an increase in authorized common stock.

Clearside Biomedical's proxy statement outlines proposals for the 2025 annual meeting, including director elections, executive compensation approval, auditor ratification, and an increase in authorized common stock.

Clearside Biomedical will hold its annual stockholders meeting on June 20, 2024, to elect directors, approve executive compensation, and ratify the selection of Ernst & Young LLP as independent auditors.

Clearside Biomedical's proxy statement highlights the company's progress in suprachoroidal drug delivery and upcoming data readout for its CLS-AX wet AMD program.

Hatteras Venture entities have updated their Schedule 13D filing for Clearside Biomedical, Inc., reporting zero beneficial ownership for the funds while associated individuals retain minor holdings.

Stephen Boyd Wiles has reported a beneficial ownership of 5.2% of Clearside Biomedical, Inc.'s common stock as of March 31, 2025, indicating a significant passive investment.

A group led by Bradford T. Whitmore has disclosed a combined beneficial ownership of 8.6% of Clearside Biomedical, Inc.'s common stock as of December 31, 2024.